SOLO3: Phase III Trial of Olaparib vs Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and Germline BRCA Mutation

May 31 - June 4, 2019; Chicago, Illinois
Olaparib treatment was associated with significant improvements in ORR and PFS vs nonplatinum chemotherapy for patients with platinum-sensitive relapsed ovarian cancer and germline BRCA mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 255 KB
Released: June 11, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Tesaro

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

La Dra. Maria-Pilar Barretina-Ginesta, comparte ideas sobre el papel evolutivo de la inmunoterapia en el manejo del cáncer de endometrio avanzado o recurrente, de Clinical Care Options (CCO)

person default Maria-Pilar Barretina-Ginesta, MD Released: July 29, 2021

医学博士 Maria-Pilar Barretina-Ginesta 分享了 Clinical Care Options (CCO) 关于免疫疗法在管理晚期或复发性子宫内膜癌方面不断发展的作用的见解

person default Maria-Pilar Barretina-Ginesta, MD Released: July 29, 2021

La dottoressa Maria-Pilar Barretina-Ginesta condivide idee sul ruolo in evoluzione dell'immunoterapia nel gestire tumore endometriale avanzato o recidivo, da Clinical Care Options (CCO)

person default Maria-Pilar Barretina-Ginesta, MD Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue